Genmab reported 306M in Selling and Administration Expenses for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Agios Pharmaceuticals AGIO:US $ 27.15M 2.06M
Alexion Pharmaceuticals ALXN:US $ 342.9M 101.5M
Amarin AMRN:US 102.96M 4.24M
Amgen AMGN:US $ 1.31B 79M
AstraZeneca AZN:LN 2.99B 412M
Bayer BAYN:GR 3.77B 19M
Biomarin Pharmaceutical BMRN:US $ 183.33M 828K
Bluebird Bio BLUE:US $ 68.28M 10.3M
Exelixis EXEL:US $ 101.56M 3.06M
Fresenius Medical Care FME:GR 731M 99.18M
Galapagos GLPG:NA 45.45M 15.51M
Genmab GEN:DC 306M 42M
GlaxoSmithKline GSK:LN 2.5B 6M
GN Store Nord GN:DC 1.17B 55M
GRIFOLS GRF:SM 249.86M 7.28M
H. Lundbeck A/S LUN:DC 1.59B 15M
Hikma Pharmaceutical HIK:LN 232M 3M
Immunogen IMGN:US $ 10.3M 569K
Insmed INSM:US $ 60.28M 3.1M
Merck MRK:GR 1.38B 34M
Novartis NOVN:VX 3.6B 109M
Regeneron Pharmaceuticals REGN:US $ 445M 30.3M
Seattle Genetics SGEN:US $ 180.28M 15.15M
William Demant Holding WDH:DC 4.48B 503M